New drug aims to destroy lung Cancer's fuel source
NCT ID NCT06685718
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 29 times
Summary
This early-phase study tests a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives non-small cell lung cancer. About 33 adults with advanced or spreading lung cancer who have already tried other treatments will receive the drug to see if it is safe and shrinks tumors. The goal is to control the disease, not cure it, as ongoing management is expected.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Austin Health
Heidelberg, Victoria, VIC 3084, Australia
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100142, China
-
Blacktown Cancer and Haematology Centre
Blacktown, New South Wales, NSW 2148, Australia
-
Cancer Research South Australia
Adelaide, South Australia, SA 5000, Australia
-
Chungbuk National University Hospital
Cheongju-si, Chungcheongbukdo, 28644, South Korea
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215-5418, United States
-
Fondazione Irccs San Gerardo Dei Tintori Sc Oncologia
Monza, 20900, Italy
-
Fondazione Policlinico Universitario Agostino Gemelli
Roma, 00168, Italy
-
Guangdong Provincial Peoples Hospital Huifu Branch
Guangzhou, Guangdong, 510120, China
-
H Puerta de Hierro Majadahonda
Majadahonda, 28222, Spain
-
Harbour Cancer and Wellness
Auckland, 1023, New Zealand
-
Hospital Universitario 12 de Octubre
Madrid, 28041, Spain
-
Hospital Universitario Vall Dhebron
Barcelona, 08035, Spain
-
Liverpool Hospital
Liverpool, New South Wales, NSW 2170, Australia
-
Memorial Sloan Kettering Cancer Center Mskcc
New York, New York, 10065-6800, United States
-
Ohio State University
Columbus, Ohio, 43210-1132, United States
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, VIC 3000, Australia
-
Princess Alexandra Hospital
Woolloongabba, Queensland, QLD 4102, Australia
-
Samsung Medical Center
GangnamGu, Seoul Teugbyeolsi, 06351, South Korea
-
Seoul National University Hospital
Seoul, Seoul Teugbyeolsi, 03080, South Korea
-
Severance Hospital Yonsei University Health System
SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
-
Shanxi Bethune Hospital
Taiyuan, Shanxi, 030032, China
-
Sir Run Run Shaw Hospital, Zhejiang University School of Medicineqiantang Branch
Hangzhou, Zhejiang, 310018, China
-
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330006, China
-
The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch
Nanning, Guangxi, 530201, China
-
The University of Texas Md Anderson Cancer Center
Houston, Texas, 77030-4009, United States
-
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, 300060, China
-
University of Colorado
Denver, Colorado, 80202-1702, United States
-
Washington University School of Medicine Siteman Cancer Center
St Louis, Missouri, 63110-1032, United States
Conditions
Explore the condition pages connected to this study.